The U.S. Supreme Court has been asked to restore the ability to receive the abortion pill by mail. The request comes after a federal appeals court issued a temporary halt to a key Food and Drug Administration regulation. That regulation had significantly expanded access to mifepristone, a medication used for abortion.
The appeals court decision restricts the FDA’s policy allowing patients to obtain the drug through telemedicine and postal delivery. This marks the latest legal move in ongoing battles over abortion access at the federal level. The case now places the Supreme Court in a position to decide on the rule’s immediate future.
Supporters of the FDA rule argue that mail-order access expands healthcare options, especially for those in remote areas. They say it removes barriers to timely care. Opponents contend that in-person visits are necessary to ensure patient safety.
The legal challenge originated from a coalition of anti-abortion groups and doctors. They claim the FDA exceeded its authority when it removed the in-person dispensing requirement in 2021. The agency has said its decision was based on medical evidence.
The Justice Department is representing the FDA in the case. It has urged the Supreme Court to block the appeals court’s order. The department argues the lower court ruling creates confusion and disrupts long-standing regulatory standards.
The Supreme Court has not yet announced whether it will take up the matter. Justices could issue a decision quickly or schedule oral arguments. The outcome could affect abortion access nationwide.
This dispute is separate from the Court’s 2022 ruling that overturned Roe v. Wade. However, it highlights ongoing legal battles over medication abortion, which now accounts for more than half of all U.S. abortions.
The FDA first approved mifepristone in 2000. Since then, it has updated its safety protocols based on real-world data. The agency maintains the drug is safe and effective when used as directed.
